RESUMO
La hipofibrinogenemia es una complicación infrecuente pero bien conocida en el contexto de las leucemias agudas. Generalmente, se asocia a la presencia de una coagulación intravascular diseminada, aunque pueden existir otras causas, como el daño hepático o el empleo de L-asparraginasa. La literatura recoge pocos casos en que esta alteración de la coagulación esté inducida por corticoides, como el aquí presentado. Se expone el caso de un niño diagnosticado de leucemia linfoblástica aguda que desarrolló hipofibrinogenemia tras iniciar tratamiento con prednisona, y se ha realizado una revisión bibliográfica a propósito del caso (AU)
Hypofibrinogenemia is an uncommon but well-recognized complication of acute leukaemia. In most instances, it has been associated with disseminated intravascular coagulation, although other causes as liver injury or treatment with L-asparraginase could exist. The literature includes rare cases in which this coagulation disorder is induced by prednisone as our report. We report the case of a child diagnosed of acute lymphoblastic leukemia with hypofibrinogenemia during the course of treatment with prednisone and we have reviewed the literature concerning the case (AU)
Assuntos
Pré-Escolar , Humanos , Masculino , Afibrinogenemia/etiologia , Prednisona/efeitos adversos , Leucemia-Linfoma Linfoblástico de Células Precursoras/complicações , Glucocorticoides/efeitos adversosRESUMO
ATR-16 syndrome is due to alterations on chromosome 16p13.3, and is usually accompanied by alpha-thalassemia, mild-moderate mental retardation, dysmorphic facial features, skeletal and genitourinary malformations. There are no references of the combination of ATR-16 syndrome and osteosarcoma in the literature. Osteosarcoma usually has a complex karyotype, characterized by a high degree of heterogeneity of chromosomal aberrations, among which is the involvement of chromosome 16. We report a case of a patient with ATR-16 syndrome diagnosed with femoral osteosarcoma.
